drugset / Trial / NCT00396409
Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
RandomizedParallel-groupTriple-blindTreatment
Summary
Efficacy/ safety for the combination of anti-IgE (Omalizumab) and specific immunotherapy (Depigoid) in patients with not adequately controlled seasonal allergic asthma and comorbid seasonal allergic rhinoconjunctivitis.
Timeline
- Start
- 2006-02
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Depigoid | Other / unclassified | 0.5 ml | — |
| Background | Omalizumab | Monoclonal antibody | — | — |